Survey on use of radiotherapy for breast cancer following breast-conserving surgery in mainland China
ZHANG Ye, HUI Zhou-guang, ZHANG Jiang-hu, YU Zi-hao, LIU Xin-fan, JIN Jing, WANG Wei-hu, WANG Shu-lian, SONG Yong-wen, LIU Yue-ping, REN Hua, FANG Hui,LI Ye-xiong
Department of Radiation Oncology, Cancer Hospital (Insititute), Chinese Academy of Medical Sciences, Peking Union Medical College,Beijing 100021, China Corresponding author:HUI Zhou-guang, Email:drhuizg@163.com;LI Ye-xiong, Email:yexiong3@yahoo.com.cn
Abstract：Objective To evaluate the current practice of breast-conserving radiotherapy (BCR) in mainland China. Methods A questionnaire on the details of treatment pattern of BCR for early breast cancer was mailed twice to all radiotherapy centers in mainland China in 2009. The responding data were collected and analyzed. Results Of the 952 surveyed centers, 396 responded (41.6%) and 328 performed BCR. The median interval between surgery and radiotherapy was 9 weeks. Of the 328 centers with BCR, whole breast was the most common irradiation target (319 centers, 97.3%), followed by supraclavicular region (273 centers, 83.2%), axilla (138 centers, 43.3%), and internal mammary chain (85 centers, 26.8%). In 97.5% of centers (310/319), whole breast was irradiated in all candidates. Supraclavicular region and axilla irradiation was performed for lymph-node positive patients in 41.8%(114/273) and 26.8%(37/138) centers, and for ≥4 positive lymph-nodes in 31.5%(86/273) and 29.0%(/138) centers, respectively. Internal mammary chain was irradiated for tumors located in the center or inner quadrant in 72.9%(56/85) centers. Conformal radiotherapy for the whole breast was used in 51.8% centers. The median total dose was 50 Gy, all using conventional fractionations. Conclusions A consensus has been reached that radiotherapy is needed for patients receiving breast-conserving surgery and that irradiation to whole breast is necessary. However, establishment and widespread use of guidelines for BCR should be strengthened.
ZHANG Ye,HUI Zhou-guang,ZHANG Jiang-hu et al. Survey on use of radiotherapy for breast cancer following breast-conserving surgery in mainland China[J]. Chinese Journal of Radiation Oncology, 2012, 21(3): 241-245.
[1] Veronesi U, Cascinelli N, Mariani L, et al. Twenty-year follow-up of a randomized trial comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med,2002,347:1227-1232. [2] Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med,2002,347:1233-1241. [3] Clarke M, Collins R, Darby S, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival:an overview of the randomized trails. Lancet,2005,366:2087-2106. [4] Yin WB, Chen B, Tian FH, et al. The growth of radiation oncology in mainland China during the last 10 years. Int J Radiat Onocl Biol Phys,2008,70:795-798. [5] Veronesi U, Paganelli G, Viale G, et al. A randomized comparison of sentinel-node biopasy with routine axillary dissection in breast cancer. N Engl J Med,2003,349:546-553. [6] Mansel RE, Fallowfield L, Kissin M, et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer:the ALMANAC trail. J Natl Cancer Inst,2006,98:599-609. [7] Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol,1998,16:2672-2685. [8] Recht A, Come SE, Henderson IC, et al. The sequencing of chemotherapy and radiation therapy after conservative surgery for early-stage breast cancer. N Engl J Med,1996,334:1356-1361. [9] Bellon JR, Come SE, Gelman RS, et al. Sequencing of chemotherapy and radiation therapy in early-stage breast cancer:updated results of a prospective randomized trail. J Clin Oncol,2005,23:1934-1940. [10] Overgaard M, Hansen PS, Overgaard J, et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med,1997,337:949-955. [11] Overgaard M, Jensen MB, Overgaard J, et al. Postoperative radiotherapy in high-risk postmenopausal breast cancer patients given adjuvant tamoxifen. Danish Breast Cancer Cooperative Group DBCG 82c Trial. N Engl J Med,1999,353:1641-1648. [12] Ragaz J, Olivotto IA, Spinelli JJ, et al. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy:20-year results of the British Columbia randomized trial. J Natl Cancer Inst,2005,97:116-126. [13] Overgaard M, Nielsen HM, Overgaard J. Is the benefit of postmastectomy irradiation limited to patients with four or more positive nodes, as recommended in internation consensus reports? A subgroup analysis of the DBCG 82 b&c randomized trials. Radiat Onocl,2007,82:247-253. [14] Nielsen HM, Overgaard M, Grau C, et al. Study of failure pattern among high-risk breast cancer patients with or without postmastectomy radiotherapy in addition to adjuvant systemic therapy:long-term results from the Danish Breast Cancer Cooperative Group DBCG 82b and c randomized studies. J Clin Oncol,2006,24:2268-2275. [15] Goldhirsch A, Gelber RD, Castiglione M. Relapse of breast cancer after adjuvant treatment in premenopausal and perimenopausal women:patterns and prognoses. J Clin Oncol,1988,6:89-97. [16] Fowble B, Solin LJ, Schultz DJ, et al. Frequency, sites of relapse, and outcome of regional node failures following conservative surgery and radiation for early breast cancer. Int J Radiat Oncol Biol Phys,1989,17:703-710. [17] Mignano JE, Zahurak ML, Chakravarthy A, et al. Significance of axillary lymph node extranodal soft tissue extension and indications for postmastectomy irradiation. Cancer,1999,86:1258-1262. [18] Leonard C, Corkill M, Tompkin J, et al. Are axillary recurrence and overall survival affected by axillary extranodal tumor extension in breast cancer? Implications for radiation therapy. J Clin Oncol,1995,13:47-53. [19] Marks LB, Hebert ME, Bentel G, et al. To treat or not to treat the internal mammary nodes:a possible compromise. Int J Radiat Oncol Biol Phys,1994,29:903-909. [20] Obedian E, Haffty BG. Internal mammary nodal irradiation in conservatively-managed breast cancer patients:is there a benefit? Int J Radiat Oncol Biol Phys,1999,44:997-1003. [21] Fowble BL, Hanlon A, Freedman G, et al. Internal mammary node irradiation neithera decreases distant metastases nor improves survival in stage Ⅰ and Ⅱ breast cancer. Int J Radiat Oncol Biol Phys,2000,47:883-894. [22] Freedman G, Fowble BL, Nicolaou N, et al. Should internal mammary lymph nodes in breast cancer be a target for the radiation oncologist? Int J Radiat Oncol Biol Phys,2000,46:805-814. [23] Korczynska BS, Sladowska A, Bogusz BR, et al. Comparison between intensity modulated radiotherapy (IMRT) and 3D tangential beams technique used in patients with early-stage breast cancer who received breast-conserving therapy. Rep Pract Oncol Radiother,2010,15:79-86. [24] Ayata HB, Guden M, Ceylan C, et al. Comparison of dose distributions and organs at risk (OAR) doses in conventional tangential technique (CTT) and IMRT plans with different numbers of beam in left-sided breast cancer. Rep Pract Oncol Radiother,2011,16:95-102. [25] Hurkmans CW, Borger JH, Giersbergen A, et al. Implementation of a forearm support to reduce the amount of irradiated lung and heart in radiation therapy of the breast. Radiother Oncol,2001,61:193-196. [26] Smith BD, Bentzen SM, Correa CR, et al. Fractionation for whole breast irradiation:an American society for radiation oncology (ASTRO) evidence-based guideline. Int J Radiat Oncol Biol Phys,2011,81:59-68. [27] Bartelink H, Horiot JC, Poortmans P, et al. Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation. N Engl J Med,2001,345:1378-1387. [28] Antonini N, Jones H, Horiot JC, et al. Effect of age and radiation dose on local control after breast conserving treatment:EORTC trial 22881-10882. Radiother Oncol,2007,82:265-271. [29] Smith BD, Arthur DW, Buchholz TA, et al. Accelerated partial breast irradiation consensus statement from the American society for radiation oncology (ASTRO). Int J Radiat Oncol Biol Phys,2009,74:987-1001.
2012, Vol. 21 
